On therapeutic grounds, constitutive BCR signaling activation was most frequent in MCD and least frequent in EZB, but genetic alterations involving the BCR cascade occurred in all genetics subtypes, suggesting that constitutive BCR signaling is a pervasive aspect of DLBCL pathogenesis. This evidence concerns the gene BCR and diffuse large B-cell lymphoma.